CAP方案化疗辅助治疗子宫肉瘤临床疗效分析  

The Clinical Efficacy of CAP Chemotherapy Adjuvant Treatment of Uterine Sarcoma

作　　者：陈瓅[1] 林安[1] 何海新[1] 李玲[1] 

机构地区：[1]福建省肿瘤医院妇科,福建福州350014

出　　处：《中国卫生标准管理》2017年第12期76-78,共3页China Health Standard Management

摘　　要：目的分析子宫肉瘤采取环磷酰胺、多柔比星以及顺铂(CAP方案)化疗辅助治疗的临床疗效。方法选择2011年1月—2013年5月我院收治的子宫肉瘤患者42例,根据患者自愿原则分为观察组和对照组,每组各21例,所有患者均接受手术治疗,基本术式为全子宫+双附件切除术,术后对照组患者采取多柔比星辅助治疗,而观察组采取环磷酰胺、多柔比星以及顺铂辅助治疗,比较两组临床治疗效果以及不良反应情况。结果观察组总有效率为57.1%,对照组总有效率为23.8%,观察组优于对照组(P<0.05);两组患者均出现不同程度的不良反应,观察组骨髓抑制、胃肠道反应、口腔溃疡、脱发的不良反应发生率均高于对照组,但两组间对比差异无统计学意义(P>0.05)。结论环磷酰胺、多柔比星以及顺铂(CAP方案)化疗辅助治疗子宫肉瘤临床治疗效果明显,治疗后不良反应发生率以及复发率较低,临床缓解率高。Objective To observe the therapeutic effects of combination of cyclophosphamide, doxorubicin and cisplatin on uterine sarcoma. Methods Forty-two patients with uterine sarcoma were divided into observation group （21 cases） and control group （21 cases） in our hospital from January 2011 to May 2013. Patients of control group were treated with doxorubicin and patients of observation group were treated with combination of cyclophosphamide, doxorubicin and cisplatin. The efficacy of two treatments were evaluated. Results Compared with the control group, the observation group （57.1%）total effective rate was higher than that of the control group（23.8%）. The differences were statistically significant （P 〈 0.05）. The rates of common adverse reaction including bone marrow suppression, gastrointestinal reactions, oral ulcer and hair loss were higher than these of the control group, but there were no differences between two groups （P 〉 0.05）. Conclusion The therapeutic of combination of cyclophosphamide, doxorubicin and cisplatin on uterine sarcoma is effective and safe, which has a high clinical remission rate.

关 键 词：子宫肉瘤 环磷酰胺 多柔比星 顺铂 

分 类 号：R984[医药卫生—药品]